Revance Therapeutics (RVNC) Reports Publication of SAKURA 1 & SAKURA 2 Results in Plastic and Reconstructive Surgery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Revance Therapeutics (RVNC) Reports Complete Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
November 4, 2019 5:26 PM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced it has completed patient enrollment of the companys pivotal ASPEN-1 Phase 3 clinical trial for its investigational drug candidate DaxibotulinumtoxinA for Injection (DAXI) for the treatment of isolated cervical dystonia (CD), a movement disorder affecting the neck. In total, 301 adult patients were enrolled at 60 sites across the U.S., Canada and Europe.
The completion of patient enrollment in the ASPEN-1 trial marks an important milestone in our development efforts for DAXI and represents the first of many therapeutic indications we plan to pursue for our novel, long-acting... More
Revance Therapeutics (RVNC) Tops Q3 EPS by 2c
November 4, 2019 4:38 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.96), $0.02 better than the analyst estimate of ($0.98).
Revance is entering a pivotal period, given the large number of value-inflection points we have created for the company, beginning in just a few weeks with the anticipated submission of our first BLA for DAXI with the FDA, said Mark J. Foley, President and Chief... More
